Sorin Group Launches a New Complete Portfolio of Pacing, Defibrillation and Left Ventricular Leads

Sorin Group, (MIL:SRN) (Reuters Code: SORN.MI), a global medical company and a leader in the treatment of cardiovascular diseases, announced CE Mark approval and commercial launch for a comprehensive new range of pacing, defibrillation and left ventricular leads. Designed for safety and long term reliability, TILDA pacing leads, VIGILA defibrillation leads and CELERITY left ventricular lead families¹ offer multiple implant options to accommodate patients’ needs and physicians’ preferences.

While all families benefit from flexible silicone lead body, steroid eluting tips that reduce inflammation and iridium fractal coated electrodes with proven electrical performance², each lead family presents its own additional features:

• Flexible from the lead connector to the distal tip, TILDA pacing leads are designed to give physicians the instant sensation of familiarity at implant along with predictable outcomes.
• VIGILA defibrillation leads feature a symmetrical lead body and thick outer insulation. Convex shock coils embedded in silicone insulation are engineered to minimize tissue in-growth.
• Intended to improve control and handling, CELERITY left ventricular leads have a flexible co-radial body. The three pre-shaped fixation alternatives are designed to facilitate access and ensure stability in targeted pacing sites regardless of patients’ challenging coronary venous anatomies.

TILDA, VIGILA and CELERITY leads’ lasting performance and quality, combined with Sorin Group’s unique algorithms, provide reliable and individualized therapies for patients²_.

"These leads are great additions to the current Sorin Group portfolios,” said Dr David Le Froy, Consultant Cardiologist, Hammersmith Hospital, Imperial College Healthcare Trust, London, UK. "All aspects of the VIGILA, TILDA and CELERITY leads are carefully designed to enhance ease of use and handling without compromising electrical performance and safety¹,” he added. "With these new options, more patients will benefit from Sorin’s unique therapies such as SafeR™, PARAD+™ BTO™, and SonR^®, some of the most efficient algorithms on the market today.”

"Instilling greater clinical confidence by delivering high performance, reliability and value to our customers is at the core of everything we do,” commented Stefano Di Lullo, Sorin Group, President of the CRM Business Unit. "This comprehensive lead portfolio complements our state-of-the-art implantable devices perfectly and will offer significant clinical benefits to each individual patient.”

About Sorin Group
Sorin Group (www.sorin.com) is a global, medical device company and a leader in the treatment of cardiovascular diseases. The Company develops, manufactures, and markets medical technologies for cardiac surgery and for the treatment of cardiac rhythm disorders. With 3,700 employees worldwide, Sorin Group focuses on three major therapeutic areas: cardiopulmonary bypass (extracorporeal circulation and autotransfusion systems), cardiac rhythm management, and heart valve repair and replacement. Every year, over one million patients are treated with Sorin Group devices in more than 80 countries.

For more information, please visit www.sorin.com

¹ All three families are not available for sales or distribution in the USA
² Sorin Group, data on file